Dopamine D2 Receptor Stimulation Potentiates PolyQ-Huntingtin-Induced Mouse Striatal Neuron Dysfunctions via Rho/ROCK-II Activation

Carole Deyts1,2,3, Beatriz Galan-Rodriguez1,2, Elodie Martin1,2, Nicolas Bouveyron1,2, Emmanuel Roze1,2,4, Delphine Charvin1,2, Jocelyne Caboche1,2, Sandrine Bétuing1,2,5,9

1 CNRS UMR 7102, Université Pierre et Marie Curie-Paris 6, Paris, France, 2 INSERM UMR 952, CNRS UMR 7224, Université Pierre et Marie Curie-Paris 6, Paris, France, 3 Biological Sciences Division, University of Chicago, Chicago, Illinois, United States of America, 4 Service de Neurologie, Hôpital Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France, 5 Université Évry Val d’Essonne, Évry, France

Abstract

**Background:** Huntington’s disease (HD) is a polyglutamine-expanded related neurodegenerative disease. Despite the ubiquitous expression of expanded, polyQ-Huntingtin (ExpHtt) in the brain, striatal neurons present a higher susceptibility to the mutation. A commonly admitted hypothesis is that Dopaminergic inputs participate to this vulnerability. We recently extended these observations and demonstrated, in vitro, that DA accelerates two neuropathological hallmarks induced by ExpHtt: aggregation of Htt and neuronal death induced by ExpHtt in primary striatal neurons in culture, and chronic D2 antagonist treatment protects striatal dysfunctions induced by ExpHtt in a lentiviral-induced model system in vivo. The present work was designed to elucidate the signalling pathways involved, downstream D2 receptor (D2R) stimulation, in striatal vulnerability to ExpHtt.

**Methodology/Principal Findings:** Using primary striatal neurons in culture, transfected with a tagged-GFP version of human exon 1 ExpHtt, and siRNAs against D2R or D1R, we confirm that DA potentiates neuronal dysfunctions via D2R but not D1R stimulation. We demonstrate that D2 agonist treatment induces neuritic retraction and growth cone collapse in Htt- and ExpHtt expressing neurons. We then tested a possible involvement of the Rho/ROCK signalling pathway, which plays a key role in the dynamic of the cytoskeleton, in these processes. The pharmacological inhibitors of ROCK (Y27632 and Hydroxyfasudil), as well as siRNAs against ROCK-II, reversed D2-related effects on neuritic retraction and growth cone collapse. We show a coupling between D2 receptor stimulation and Rho activation, as well as hyperphosphorylation of Cofilin, a downstream effector of ROCK-II pathway. Importantly, D2 agonist-mediated potentiation of aggregate formation and neuronal death induced by ExpHtt, was totally reversed by Y27632 and Hydroxyfasudil and ROCK-II siRNAs.

**Conclusions/Significance:** Our data provide the first demonstration that D2R-induced vulnerability in HD is critically linked to the activation of the Rho/ROCK signalling pathway. The inclusion of Rho/ROCK inhibitors could be an interesting therapeutic option aimed at forestalling the onset of the disease.

**Citation:** Deyts C, Galan-Rodriguez B, Martin E, Bouveyron N, Roze E, et al. (2009) Dopamine D2 Receptor Stimulation Potentiates PolyQ-Huntingtin-Induced Mouse Striatal Neuron Dysfunctions via Rho/ROCK-II Activation. PLoS ONE 4(12): e8287. doi:10.1371/journal.pone.0008287

**Editor:** Howard E. Gendelman, University of Nebraska, United States of America

**Received** May 12, 2009; **Accepted** November 18, 2009; **Published** December 15, 2009

**Copyright:** © 2009 Deyts et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie-Paris 6 and High Q Foundation for Jocelyne Caboche and Sandrine Bétuing. Carole Deyts and Beatriz Galan-Rodriguez were grant recipients from the High Q foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: sandrine.betuing@snv.jussieu.fr

† These authors contributed equally to this work.

Introduction

Huntington’s disease (HD), a neurodegenerative disorder characterized by motor, cognitive, and psychiatric disorders [1] is caused by abnormal expansion of a CAG tract in exon 1 of the *HTT* gene. This mutation leads to an abnormal polyglutamine expansion in the N-terminal part of the huntingtin (Htt) protein. Cleavage of polyQ expanded huntingtin (ExpHtt) by caspases, leads to the release of N-terminal fragments containing the polyglutamine repeats, which can aggregate in neurites, cytoplasm, and nuclei.

Despite ubiquitous expression of Htt throughout the brain and other tissues, medium spiny GABAergic neurons in the striatum predominantly degenerate in the brain of HD patients [1]. Among various mechanisms [2] dopamine (DA) may be important in this preferential vulnerability. HD neuropathology progresses in the striatum according to the same dorsoventral gradient as local DA concentration [1,3,4]. Variations of DA concentration can modulate striatal death in various models [5,6,7]. Dopamine transporter knock-out (DAT−/−) mice display both spontaneous striatal death and behavioral alterations that resemble HD [6]. When mated to knock-in HD mice these mice showed exacerbation of HD pathophysiology and acceleration of aggregate formation [9]. We recently extended these observations and demonstrated, *in vitro*, that DA accelerates two neuropathological hallmarks induced by...
expHtt: aggregate formation and striatal neuron death [10]. On this in vitro model system, DA exerted a dual role on striatal death, via two independent pathways. One was due to reactive oxygen species and activation of the pro-apoptotic cJun-N terminal Kinase [JNK] pathway, the other one was specifically linked to D2 receptor stimulation and aggregate formation. Importantly, D2 antagonist treatments in vitro and in vivo protected from aggregate formation and striatal dysfunctions induced by ExpHtt [10,11].

Aggregate formation is known to be involved in the destabilization of microtubules and disorganization of the dendritic arbors, which are early events in the pathogenic mechanisms involved in HD [12,13,14,15,16]. One critical intracellular signalling pathway involved in actin cytoskeleton rearrangements and neurites elongation is the Rho/ROCK pathway [17,18,19]. This pathway has recently been shown to be involved in aggregate formation and cell death induced by ExpHtt, in drosophila or cell line models [20,21,22]. In the present study, we show a coupling of D2 receptor to this signalling pathway. The inhibition of ROCK activity using selective inhibitors, of knock-down of ROCK-II expression reversed D2 agonist-mediated aggregate formation, neurite retraction and neuronal death induced by ExpHtt. By contrast, these treatments failed to affect neuronal dysfunctions induced by ExpHtt itself. We thus conclude that striatal neurons vulnerability in HD may be at least in part, mediated by the Rho/ROCK signalling pathway. The inclusion of Rho/ROCK inhibitors could be an interesting therapeutic option aimed at forestalling the onset of the disease.

Results

DA-Mediated Potentiation of Aggregates Formation and Neuronal Death Induced by ExpHtt in Striatal Neurons Involved D2R but Not D1R Stimulation

Using primary cultures of striatal neurons expressing exon 1 of Huntingtin with a polyglutamine stretch (103Q; ExpHtt) fused to EGFP, we recently showed that DA, via D2 receptor stimulation, potentiates aggregate formation and neurodegeneresce induced by ExpHtt. These results were based on pharmacological studies made on primary striatal neurons from WT or knock-out mice for D2 receptors (D2R) [10]. Other in vitro studies documented that D1 receptors (D1R) play a role in mutant huntingtin-mediated aggregates formation and apoptosis [23,24,25]. In order to clarify the specific contribution of D1R and D2R on DA-mediated potentiation of aggregates formation and neuronal death in our model system, we used molecular tools to abrogate D1R and D2R expression. We first showed expression of both D1R and D2R in primary cultures from E14 striatal neurons after 7 days in vitro (DIV 7) (Fig. 1A–D). Of interest, both the full-length and spliced version of D2 receptors (D2L and D2S) were present in these striatal neurons (Fig. 1A). Specific invalidation of D1R and D2R mRNA and protein expression was achieved following siRNA transfection in striatal neurons (Fig. 1). Then, using this siRNA molecular approach, we focused on the role of both D1 and D2 receptors in DA-mediated potentiation of aggregates formation and neuronal death induced by ExpHtt. We took advantages of GFP-tagged cDNAsto visualize expression and localization of Htt and ExpHtt in transfected neurons (Fig. 2A). As a consequence, aggregates of ExpHtt was visualized owing to GFP labelling. Knockdown of D2R (both D2L and D2S) but not D1R, using specific siRNAs resulted in a total inhibition of DA-induced aggregates formation (Fig. 2B), as previously demonstrated from D2R-knock out mice [10]. As expected, D2R siRNA only partially inhibited DA-mediated neuronal death in ExpHtt expressing neurons (Fig. 2C). Furthermore, specific knockdown of D1R did not affect neuronal death in ExpHtt expressing neurons (Fig. 2C). Thus, having shown the specific involvement of D2R but not D1R stimulation in aggregate formation and neuronal death, we used for the following experiments a specific D2R agonist, quinpirole (Quin), to study

Figure 1. Validation of D1R and D2R specific siRNA in primary striatal neurons. A–D: primary striatal neurons were transfected or not (Control) with Cont siRNA, D1R siRNA and D2R siRNA. After 72 hours, mRNAs were extracted followed by RT-PCR (A and B) and protein expression levels detected by immunoblot (C and D). A: RT-PCR of D1R gene and, B: RT-PCR D2R. Note the presence of both D2R long and short isoforms. For A and B: ARP gene was used as housekeeping gene. B and D: immunoblot using specific anti-D1R (C), and specific D2R (D) antibodies. β-tubulin was used for control loading. doi:10.1371/journal.pone.0008287.g001
D2R signalling pathway involved in the potentiation of ExpHtt-induced cellular dysfunctions.

D2 Receptor Stimulation Potentiates Neuritic Retraction and Growth Cone Collapse Induced by ExpHtt in Striatal Neurons

Once aggregates of ExpHtt are formed, they destabilize microtubules and disrupt the cellular architecture [15]. We first investigated whether ExpHtt had any effect on the dynamic organization of the cytoskeleton and neuritic outgrowth in our model system. Using MAP2 (Microtubule-Associated-protein) immunostaining we analyzed the mean neuritic length of transfected neurons (Fig. 3A, C). Statistical analyses revealed a significant decrease of neuritic length (~25%) in ExpHtt expressing neurons when compared to Htt-transfected cells. We then analyzed a possible potentiation of DA and/or D2-Receptor stimulation on ExpHtt-mediated neuritic retraction. All experiments were performed in the presence of anti-oxidants, in order to avoid indirect effect of DA auto-oxidation. DA and quinpirole treatments potentiated significantly the reduction of neuritic length induced by ExpHtt alone (Fig. 3A, C). Importantly, DA and quinpirole treatments also induced a significant decrease of neuritic length in non-transfected striatal neurons (~30%; data not shown) as well as in Htt-expressing neurons (Fig. 3A, C). In both Htt- and ExpHtt-expressing neurons, DA effects on neuritic retraction were reversed by the selective D2 receptor antagonist, raclopride (Fig. 3C). This indicates that the major effects exerted by DA on neuritic retraction are mediated by D2 receptor stimulation.

Neuritic retraction is accompanied by a disorganization of actin filaments that can be visualized by rhodamine-phalloidin labelling. The filaments of actin are concentrated in filopodes and lamellipodes of growth cones (Fig. 3B). Actin filaments are mainly observed at the tips of the neurites and present very well structured and large growth cones, in most neurons expressing Htt. About 20% of collapse was found in Htt-expressing neurons. About 42% of collapse was observed in ExpHtt-expressing neurons (42% of collapse) (Fig. 3B, D). This collapse was even higher upon quinpirole treatment, in both Htt and ExpHtt transfected neurons (30% and 65%, respectively, Fig. 3D), indicating that D2 receptor stimulation promotes a disorganization of actin filaments.

D2-R Mediated Neuritic Retraction and Growth Cone Collapse Is Associated with ROCK-II Activation in Striatal Neurons

Various signalling pathways participate in the dynamic reorganization of the cytoskeleton and neuritic elongation, among which the Rho/ROCK signalling pathway is thought to play a key role [17,18,19]. We thus investigated a possible involvement of this pathway in neuritic retraction induced by ExpHtt in the presence or not of the D2 agonist treatment. The ROCK pharmacological inhibitors Y27632 and Hydroxyfasudil were used as a first approach. These inhibitors, applied 30 minutes prior to, and during quinpirole treatment, reversed D2-mediated effects on neuritic retraction in Htt- and ExpHtt-expressing neurons (42% of collapse) (Fig. 3B, D). This collapse was even higher upon quinpirole treatment, in both Htt and ExpHtt transfected neurons (30% and 65%, respectively, Fig. 3D), indicating that D2 receptor stimulation promotes a disorganization of actin filaments.
Figure 3. D2 receptor stimulation potentiates neuritic retraction and growth cone collapse induced by ExpHtt in striatal neurons. A) Immunohistochemical detection of MAP2 protein (red) was performed on striatal neurons transfected with either Htt or ExpHtt (GFP) and treated or not for 14 hours with quinpirole (10 μM). Nuclei were labelled using Hoechst (blue). The white arrow in the merge panel points to a neurite in transfected neurons. B) Phalloidin labelling of F-actin was assayed to visualize growth cone on Htt and ExpHtt-expressing striatal neurons. White arrows and insert in the merge panel depict a growth cone in a transfected neuron. C) Quantification of mean neuritic length in transfected neurons was determined from MAP2 staining using ImageJ software in Htt (white bars) and ExpHtt (black bars)-expressing neurons, treated or not with dopamine (DA, 100 μM), quinpirole (Quin, 10 μM) or DA plus raclopride (1 μM) for 14 hours. D) Quantification of growth cone collapse was determined on phalloidin staining in Htt (white bars) and ExpHtt (black bars)-transfected neurons treated or not with quinpirole (10 μM) for 14 hours. C and D) Data were analyzed from at least 3 independent experiments (100 transfected neurons per condition and per experiment) and expressed as mean±SEM. (***P<0.001, ns: non significant).

doi:10.1371/journal.pone.0008287.g003
Figure 4. D2-R mediated neuritic retraction and growth cone collapse is associated with ROCK-II activation in striatal neurons. A) Quantification of mean neuritic length in neurons transfected with Htt (white bars) or ExpHtt (black bars) was determined from MAP-2 staining. Transfected neurons were pre-treated with ROCK pharmacological inhibitors Y27632 (10 μM) or Hydroxyfasudil (10 μM) 30 minutes prior to and during quinpirole treatment (10 μM) (14 hours). Data are expressed as mean±SEM from 3 independent experiments (100 transfected neurons per condition and per experiment) (**P<0.001). B) Striatal extracts from adult mouse (striatal extracts), striatal neurons in culture (striatal cultures) and HEK293 cells extracts (HEK cells) were processed for Western-blot with specific antibodies against ROCK-I (left) and ROCK-II (right). Similar amounts of proteins were loaded in each case. β-tubulin was used for control loading. Note the high expression level of ROCK-II in both striatal extracts and culture when compared to ROCK-I expression. C) Control siRNA (50 nM) or siRNA targeting ROCK-II (50 nM) were transfected in primary striatal neurons for 72 hours. Extracts from siRNA-transfected or non-transfected (control) neurons were processed for Western-blot with specific antibodies against ROCK-II and β-tubulin. Note the knock-down of ROCK-II expression. D) Quantification of mean neuritic length in neurons transfected with Htt (white bars) or ExpHtt (black bars) after quinpirole treatment (10 μM) alone or in the presence of control siRNA (50 nM) or ROCK-II siRNA (50 nM). Data are expressed as mean±SEM from 3 independent experiments (100 transfected neurons per condition and per experiment). (**P<0.005, **P<0.05). E) Quantification of growth cone collapse in neurons transfected with Htt (white bars) or ExpHtt (black bars) after quinpirole treatment (10 μM) for 14 hours alone or in the presence of ROCK inhibitors (10 μM) or ROCK-II siRNA (50 nM). Data are expressed as mean±SEM from 3 independent experiments (100 transfected neurons per condition and per experiment). In these experiments, neurons transfected with control siRNA showed no significant difference with non-transfected neurons (control) alone (**P<0.001).

doi:10.1371/journal.pone.0008287.g004
ROCK-II signalling is implicated, downstream D2 receptors, in the potentiation of ExpHtt aggregate formation.

**D2-R Stimulation Potentiates ExpHtt-Induced Neuronal Death via ROCK-II Activation**

We previously showed [10] that D2 agonist treatment potentiated striatal death induced by ExpHtt. Cell survival was analyzed 24 hours after transfection by appreciation of nucleus morphology (DNA fragmentation) by Hoechst staining (Fig. 7A). Quinpirole significantly potentiated ExpHtt-induced neuronal death without affecting cell survival in Htt-expressing neurons. The ROCK inhibitors Y-27632 or Hydroxyfasudil and ROCK-II siRNA totally rescued toxicity induced by the D2 agonist in ExpHtt-expressing striatal neurons with no effects against toxicity induced by ExpHtt itself (Fig. 7B). Altogether, these data indicate that the Rho/ROCK-II signalling pathway is a major pathway downstream D2 receptor for mediating toxicity in ExpHtt-expressing neurons.

**Discussion**

In the present work, we wished to analyze how DA via DA receptors stimulation might account for aggregate formation and potentiation of neuronal death in ExpHtt expressing striatal neurons. We first confirm our previous results [10,11] showing that DA potentiation of ExpHtt toxicity is mediated via D2R but not D1R stimulation, in our model system, i.e. in striatal neurons expressing a truncated version of ExpHtt. We show the first evidence for a coupling of D2 receptors to the Rho/ROCK-II signalling pathway. In cultured striatal neurons, inhibition of this pathway reversed DA/D2 receptor-mediated neuritic retraction, growth cone collapse, aggregate formation and neuronal death induced by ExpHtt in the presence of D2 agonist. By contrast with findings in other model systems of HD (Drosophila, and HEK cells), we failed to demonstrate a clear involvement of ROCK in ExpHtt induced cellular phenotypes in striatal neurons.

Neurodegeneration in HD occurs most prominently in the basal ganglia and neocortex. Striatal neurons show a range of vulnerabilities in Huntington’s disease. Medium Spiny Neurons (MSNs) are the first affected striatal cells while interneurons are spared, even at a late stage of the disease. Among the MSNs, the GABAergic/enkephalinergic, which preferentially express D2 receptors and project to the external segment of globus pallidus (Gpe) tend to degenerate before the substance P/dynorphinergic striato-nigral neurons expressing D1 receptors [29,30,31]. In HD patients, primates and mouse models of HD, aggregates appear first in the neuropil [9,14,16,32,33,34], where they are thought to be toxic by poisoning the axonal transport [11,16,35]. The reduction of these aggregates leads to an improvement of the phenotype in HD mice [36]. Interestingly, the Substantia Nigra (SN) and the GPe, which receive afferents from the D2R-expressing striatal neurons, are the first brain areas where neuropil aggregates appear, in mice and human [16,34,37,38]. Hyperdopaminergic HD mice display an accelerated clinical and neuropathological phenotype with early formation of neuropil aggregates that predominate in the GPe [9], which express D2R but not D1R. In primary culture of striatal neurons expressing ExpHtt, D2 receptor stimulation increases the formation of neuropil aggregates, while striatal neurons from D2R knock-out mice fail to show any vulnerability to DA for aggregate formation [11]. By contrast, D1R stimulation did not influence the total number of mutant Htt aggregates in SK-N-MC expressing ExpHtt (N-term-103Q) [24]. These observations were strengthened in the present work, where D2R- but not D1R- siRNAs prevented DA-
mediated effects on aggregate formation. Thus, altogether, these findings suggest that D2 receptor stimulation plays a key role in GABAergic/MSN vulnerability to ExpHtt, via potentiation of neuropil aggregates and axonal poisoning. Other deleterious effects of D2 receptor stimulation on ExpHtt induced neuronal dysfunctions were recently unraveled (41). In an elegant study, the authors showed that D2 receptor stimulation increased ExpHtt-induced deficiency of mitochondrial complex II protein activity, which plays a key role in oxidative energy metabolism. In cellular models expressing the full length mutant Htt, immortalized mutant STHdhQ111, striatal neuronal progenitor cell lines or striatal neurons from YAC128 mice, D1R stimulation but not D2R is involved in DA-mediated cell death and potentiation of glutamate toxicity [23,25]. In these studies, D1R-mediated effects were critically linked to increased calcium influx. Thus, depending on the expression of the full length or the cleaved fragment of

Figure 5. DA and quinpirole activate Rho/ROCK pathway on striatal neurons. A) Western-blot detection of Rho-GTP (top) along with Total Rho (middle) and β-tubulin (bottom) after 15 minutes of treatment with DA (100 μM) and quinpirole (10 μM) in non-transfected striatal neurons. B) Quantification of Rho-GTP activity from 3 independent experiments. Total Rho was expressed as Arbitrary Unit (AU). Note the significant increase of Rho-GTP/Total Rho after 15 minutes of DA (Grey bar) and quinpirole (Black bars) treatment (*P<0.05). C) Immunocytochemical detection of P-Cofilin (green) and MAP2 (red) proteins 20 minutes after quinpirole treatment (10 μM, lower panel) and in Control conditions (upper panel). Nuclei were labelled using Hoechst (blue). D and E) Quantification of P-Cofilin positive neurons (n = 3 independent experiments, 100 neurons per experiment) using Metamorph software after quinpirole treatment alone or in the presence (D) of pharmacological inhibitors of ROCK, Hydroxyfasudil (10 μM) and Y-27632 (10 μM) or (E) after transfection of siRNA ROCK-II. B, D and E, Data are expressed as mean±SEM (**P<0.005, *P<0.05).

doi:10.1371/journal.pone.0008287.g005
Figure 6. D2-R increases ExpHtt aggregates formation via ROCK-II activation in striatal neurons. A) ExpHtt aggregates detection based on GFP fluorescence in primary striatal neurons transfected with ExpHtt (tagged with GFP) for 10 hours and MAP2 immunostaining (red). Note, at this time point, that ExpHtt present either a diffuse expression pattern (top panel) as well as aggregates formation (bottom panel). B) Quantification of ExpHtt-transfected neurons with aggregates after quinpirole treatment (10 μM) for 10 hours alone or in the presence of pharmacological inhibition of ROCK (Y27632, 10 μM and Hydroxyfasudil, 10 μM) or ROCK-II siRNA (50 nM). Data are expressed as mean±SEM from 3 independent experiments (100 transfected neurons per condition and per experiment) (**P<0.001, ns: non significant).

doi:10.1371/journal.pone.0008287.g006

mutant Htt, either D1R or D2R seem to be differentially involved in DA-mediated toxicity on striatal neurons.

In our in vitro model system, D2 receptor stimulation increased neuritic retraction and growth cone collapse in mutant- but also normal Htt-expressing neurons. This observation corroborates in vivo data showing that D2 receptors stimulation results in pruning of the terminal arbor of substantia nigra pars compacta (SNpc) DA neurons [39,40]. Furthermore, the genetic invalidation of D2 receptor in mice resulted in a significant increase in terminal tree size of these neurons, as well as the density of varicosities in the caudate-putamen [42,43]. We can thus hypothesise that the disorganization of the neuritic arbors described in HD might be, at least in part, due to local D2 receptor stimulation. D2 receptors are classically described as negative regulators of the cAMP/PKA pathway, via coupling to Gz/o [41]. They can also couple to phospholipase (PLCβ) via Gq, mobilize intracellular calcium stores [42] and activate the MAPK/ERK signalling cascade [42,43]. Dopaminergic stimulation of D2 receptors can also activate or inhibit the Akt phosphorylation level (Thr308), depending on the time of stimulation, short or long, respectively [43,44]. In the present study, we present the first evidence for a coupling between D2 receptors and the Rho/ROCK signalling pathway. Such coupling was suggested previously, by a study showing that D2-mediated activation of Phospholipase D (PLD) was abolished by preincubation of the cells with C3 exoenzyme, a specific inhibitor of the Rho proteins [27]. Other G protein-coupled receptors have been described for their ability to activate Rho proteins. The classical activator of this pathway is the lysophosphatidic acid (LPA) receptor which acts through G12/G13 to activate RhoA and ROCK and lead to neuritic retraction and growth cone collapse [45,46,47] The details of the mechanism by which D2 receptor stimulates Rho proteins remain unclear but could involve the scaffolding proteins β-arrestin that have been associated with the activation of Rho downstream Angiotensin A2 receptors [48] and are known to be critical for D2 receptor internalization [49].

ROCK proteins are principal mediators of RhoA activity in the nervous system where they have been largely reported as regulators of neuritic length and growth cone collapse [50]. Screening for biologically active molecules that inhibit polyglutamine aggregation, lead to the identification of a pharmacological ROCK inhibitor, Y-27632 [21,22] When Y-27632 was administrated in a Drosophila model of HD, it reduced Htt-exon1 (93Q) induced neurodegeneration. In HEK cell line expressing Htt exon1 (72Q), it was necessary to knock-down both ROCK-I and Protein Kinase C-related protein (PRK2) proteins to abolish polyglutamine aggregation [21] In Neuro2a cells expressing Htt-exon1 (150Q), knock-down of ROCK-II and ROCK-I reduced aggregation [51]. In striatal neurons, in vitro and in vivo, we found a poor expression of ROCK-I, while ROCK-II was strongly expressed. Global inhibitors of ROCK or knock-down of ROCK-II expression, failed to reverse neuronal dysfunctions induced by ExpHtt by itself. However, the pharmacological inhibitor of ROCK, as well as ROCK-II-siRNAs, reversed D2-mediated effects on ExpHtt-induced phenotype. We thus propose that, in striatal neurons, the Rho/ROCK-II signalling pathway is critically involved in D2-mediated vulnerability in HD. Interestingly, ROCK proteins have been proposed as a promising therapeutic target in various neurological conditions [52]. In the CNS, inhibition of ROCK using Y27632 promotes axon growth after spinal cord injury in experimental animal models [53] and reduces the expression of amyloid-β peptide in a mouse model of Alzheimer’s disease [54].

Because long term pharmacological blockade of D2 receptors may be poorly tolerated in patients [55,56], the inclusion of Rho/ROCK inhibitors could be an interesting therapeutic option to target the vulnerability of D2-R expressing striatal neurons in HD.

Materials and Methods

Mouse Husbandry

Mice were housed in a temperature-controlled room maintained on a light/dark cycle. Food and water were available ad libitum. Experiments were performed in accordance with standard ethical guidelines (U.S. National Institutes of Health publication n° 85-23, revised 1985, and the European Committee Guidelines on the Care and Use of Laboratory Animals directive 86/609/EEC).
Primary Striatal Culture and Drug Treatment

Primary striatal neurons were dissected out from 14 days old embryos from pregnant Swiss mice (Janvier, Le Genest Saint Isle, France) as previously described [43]. After dissociation, cell pellets were resuspended in Neurobasal medium supplemented with B27 (Invitrogen), 500 nM L-glutamine, 60 µg/ml Penicillin-streptomycin and 25 µM β-mercapto-ethanol and then plated on poly-L-lysine-coated 24-well (1,33 ± 10^5 cells by well) or 6-well plates (6,321 ± 10^5 cells by well) at 37°C in a humidified 5% CO₂ incubator. Using this preparation, the cell culture contains in majority cells from neuronal and not glial origin.

After 7 days in culture, neurons grown in 24 well plates, were transiently transfected with GFP-tagged Htt constructs (provided by HDF Resource Bank, UCLA) encoding the first exon of human Htt containing either 25 (Htt) or 103 (ExpHtt) continuous CAA or CAG repeats. The sequence encoding an enhanced Green Fluorescence Protein (GFP) was inserted in frame at the C-terminus of each construct. Three hours and half after transfection, the medium was replaced by the complete Neurobasal Medium containing dopamine (DA, 100 µM, Calbiochem), quinpirole (Quin, 10 µM RBI). Cells were then replaced at 37°C for the appropriate time. For the pharmacological treatments, Y-27632, (10 µM; Tocris) Hydroxyfasudil (10 µM; Sigma) or Raclopride (Raclo, 1 µM Sigma) were added 30 min before and during quinpirole treatment.

RNA Interference

SiRNAs targeted dopamine D1 (D1R), both isoforms of dopamine D2 (D2R) receptors, D2Long and D2Short (D2LR and D2SR, respectively) and ROCK-II were designed to specifically interfere with dopamine D1R, D2R and ROCK-II expression. The target sequences were as follows: D1R, 5'-CCUGGAAGAUGCCGAGGAU-3'; D2R, 5'-CCAGAGAG-GACCCGGUAUA-3' and ROCK-II, 5'-CAAUGAAGCUCUUAGUAA-3' (Eurogentec). Neurons were transfected at day in vitro 4 (DIV) with 50 nM of siRNA against D1R, D2R and ROCK-II or siRNA control (Cont siRNA #2, Ambion). After 72 hours of silencing, primary neurons were used for transfections experiments and drug treatment.

RNA Isolation and RT-PCR

Seventy two hours after transfection with D1R or D2R siRNAs, total mRNA was isolated using RNeasy mini kit (Qiagen) following the manufacturer’s instructions. Reverse transcription was per-
formed using SuperScript III (Invitrogen) followed by cDNA amplification with specific primers (Eurogentec S.A.). The nucleotide sequences of the primers were as follows: D1R, forward 5'-TTCTTCCGTGATGGCGTG-3'; D2LR, reverse 5'-GCTTGACCCACCTTGGAGAGA-3'; reverse 5'-GTTGCTATGTAAGCCTG-3' and D2SR, forward 5'-CACCACCTCAAGGATTGCTGCGC-3', reverse 5'-GTTGCTATGTAAGCCTG-3'. Amplification of Arginin Rich Protein (ARP), used as an housekeeping gene, was performed using the following primers forward 5'-GAACGTGCTGTCCTCGTCA-3', reverse 5'-AAACCTTTCGACGAAGGAGGT-3'.

Immunocytochemistry and Histological Analysis

Striatal neurons were fixed in 2% paraformaldehyde in PBS for 40 minutes at room temperature and permeabilized with Methanol/Acetone (1:1 ratio) for 10 min at 4°C. After washing with PBS, cells were preincubated with blocking buffer (10% Normal Goat Serum in PBS) at room temperature for 1 h and then incubated with primary antibody in PBS overnight at 4°C: mouse anti-microtubule-associated protein 2 (1/1000, Sigma), rabbit anti-P-Cofilin (1/500, Cell Signaling), and mouse anti-Huntingtin (1/1000, Chemicon). Cells were rinsed with PBS and incubated for 2 h at room temperature with the secondary antibody, Cy3-conjugated anti-mouse IgG (1/2000, Jackson Laboratories) or Rabbit-FITC (1/200, Sigma). To analyze the nuclei morphology, cells were stained with Hoechst (1/20000 in PBS) for 5 min at room temperature, followed by three PBS washes. Aggregates of ExpHtt were visualized by GFP staining. The cells were mounted under cover slips using a Vectashield medium (Vector Laboratories) and examined with a Leica DM4000B fluorescence microscope (X40). The percentage of transfected neurons containing aggregates of Exp-Htt was determined by counting neurons containing aggregated GFP versus diffuse GFP. Neurons containing condensed or fragmented nuclei were scored as dying cells. The neuritic length was evaluated by tracing the neurites using the software ImageJ (version 1.34 s). The actin cytoskeleton staining was performed by incubating fixed cells with phalloı¨dine TRITC (1/500) diluted in PBS-2% BSA for 20 min at room temperature. Each experiment was conducted in triplicate, and at least 100 transfected neurons were randomly analyzed in each experiment.

Cell Extracts and Western Blot Analysis

Samples were prepared from neurons and HEK293 cells homogenized in a boiling lysis buffer containing 1% SDS and 1 mM sodium orthovanadate and briefly sonicated. Equal amounts of proteins were resolved by SDS-PAGE gels and transferred to PVDF membrane (Amersham). After blocking in 5% nonfat dry milk (for ROCK-I and ROCK-II) or 5% BSA (Bovine Serum Albumin, SIGMA) for D1R and D2R immunoblotting in TBS for 1 h at room temperature, membranes were incubated overnight at 4°C with primary antibodies, rabbit polyclonal anti-ROCK-I anti-ROCK-II (1/500, Santa Cruz), mouse monoclonal anti-D1R (1/250, Millipore), rabbit polyclonal anti-D2R (1/1000, Millipore) and mouse monoclonal anti-ß-tubulin (1/5000, Sigma), and revealed with appropriate anti-rabbit or anti-mouse peroxi-dase-conjugated secondary antibodies (1/5000, Jackson ImmunoResearch Laboratories) and the enhanced chemiluminescent (ECL) detection system (Pierce).

Rho Activation Assay

Rho activation was analyzed using Rho assay kit (Upstate Biotechnology). After DA (100 µM) and quinpirole (10 µM) treatments for 15 min, cells were lysed in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM sodium ortho- vanadate, 50 mM MgCl2, 0.1% SDS, 1% Nonidet P-40, 1% sodium deoxycholate and complete protease inhibitor cocktail (Sigma) for 15 min at 4°C. The Rho active form, Rho-GTP, was specifically immunoprecipitated from these lysates incubating with Rho Assay Reagent (Rhotekin fused to the Rho Binding Domain on agarose beads) for 45 min at 4°C on a rotator. After a short spin, the pellet beads were washed three times with lysis buffer and resuspended in 25 µl of 2X Laemmli buffer. Rho-GTP activated bound to rhotekin-agarose beads was subjected to 15% SDS-PAGE, followed by Western blotting with mouse monoclonal anti-Rho (A,-B,-C) antibody (1/250, Upstate).

Statistical Analysis

All data were statistically analyzed using GraphPad Prism (GrahPad Software Inc., San Diego,CA). Two-way ANOVA followed by post hoc Bonferroni’s test was carried out and for all statistical analyses the difference between comparisons was considered to be significant when P<0.05.

Author Contributions

Conceived and designed the experiments: CD ER JC SB. Performed the experiments: CD BGR EM DC JC SB. Analyzed the data: CD BGR EM DC JC SB. Contributed reagents/materials/analysis tools: NB JC ER DC JC SB. Performed the statistical analyses: CD BGR EM DC JC SB. Wrote the paper: CD JC SB.

References

1. Vonaintal JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, et al. (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44: 539–577.
2. Ritz E, Sallou F, Caboche J (2000) Pathophysiology of Huntington’s disease: from huntingtin functions to potential treatments. Curr Opin Neuro 21: 497–503.
3. Cass WA (1997) Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. Brain Res 235: 93–103.
4. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57: 369–384.
5. Bowyer JF, Clausing P, Schmued L, Davies DL, Binienda Z, et al. (1996) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235: 93–103.
6. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY (1982) Proliferative and degenerative changes in striatal spiny neurons in Huntington’s disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci 11: 3877–3887.
